Collegium Completes Acquisition of Ironshore Therapeutics
September 04, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
August 28, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Second Quarter 2024 Financial Results
August 08, 2024 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2’24 GAAP Net Income of $19.6 Million,...
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
July 29, 2024 06:00 ET
|
Collegium Pharmaceutical, Inc.
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year – – Transaction Expected to...
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
June 13, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports First Quarter 2024 Financial Results
May 09, 2024 16:02 ET
|
Collegium Pharmaceutical, Inc.
– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net...